The Newsletter
The business of foot and ankle, without the corporate filter.
Products. People. Deals. Lawsuits. Numbers. Rumors.
Independent coverage of the foot and ankle industry since 2011.
Get it in your inbox
Free. Monthly-ish. Unsubscribe whenever.
From the Archive
The Artelon Playbook: How to Engineer an Exit
Stryker pulls the trigger. Here is the five-step playbook that got Artelon there.
The Treace Report: Inside Culper Research's Short Thesis
An activist short seller accuses Treace of fraudulent coding. We read all 21 pages.
The Nitinol Wars: CrossRoads, MedShape, and Arthrex Escalate
Everyone has a nitinol staple. These three are trying to do more with it.
CrossRoads Sells to DePuy Synthes, Plus the Bunion DTC Marketing War
J&J finally makes its move, and a look at who is winning direct-to-patient.
Innovation Is Not Dead: Up-and-Comers Worth Watching
Novel products not yet mainstream, and at least one about to be acquired mid-issue.
Introducing the Golden Demobone Awards
FAN's first annual awards for the products, people, and deals that defined the year.
AOFAS Savannah Preview: MIS Achilles and the New Launches
Unsolicited advice for exhibitors and surgeons, plus a challenger to Arthrex PARS.
Browse the Library
Who bought whom, what it cost, and who's next.
New implants, jigs, and systems as they hit the field.
Startups and challengers before the market notices.
Numbers, reimbursement, short reports, and market reads.
FAN's annual awards for the products and people of the year.
AOFAS and ACFAS, from the exhibit hall floor.
The business side of running a foot and ankle practice.
